Tuesday, October 25, 2011

Female Shift Workers May Be At Higher Risk Of Heart Disease

Women hospital staff working night shifts may be compromising their own health as they try to improve the health of patients, Dr. Joan Tranmer told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Dr. Tranmer's study investigated the connection between shift work and risk factors for heart disease in female hospital employees who worked both shift and non-shift rotations.
As a former nurse familiar with shift work and because of her concern about the health of the female hospital work force, Dr. Tranmer questioned whether late nights were taking their toll on the health of her fellow hospital employees. "As I walked through the hospital and talked with my colleagues, I was concerned about what I was seeing in a lot of the workers," she said. "We did not know if this is related to shift work or other aspects of hospital work".
Her study reinforced what she observed about the health of female hospital employees. Dr. Tranmer studied 227 women ranging in age between 22 and 66 (with a mean age of 46) from two hospitals in southeastern Ontario. The study included not only nurses but a variety of staff, including administrative employees as well as lab and equipment technicians, who worked a variety of rotations.

She examined each of the women's possible risk factors associated with metabolic syndrome. The syndrome's five indicators are abdominal obesity (elevated waist circumference), high blood pressure, elevated blood glucose, elevated triglycerides, and low levels of high-density lipoprotein (HDL) cholesterol, also known as 'good cholesterol.' The women also completed a detailed survey about their work history and lifestyle.

The findings of this study suggest that approximately one in five middle-aged women who do shift work have at least three risk indicators for heart disease.

From the group, 17 per cent had metabolic syndrome, with at least three of the identified indicators. Thirty-eight per cent had high blood pressure. Of particular concern was the finding that 60 per cent of the participants had a waist circumference greater than 80 cm (31.5 inches).

Abdominal obesity and elevated waist circumference are good predictors for risk of developing heart disease, stroke, high blood pressure, cholesterol and type 2 diabetes. The greater your waist circumference, the higher your risk of developing these conditions.

The study found that age and current shift work status were significantly associated with increased risk. Women over 45 years, those who had reached menopause, had a shift work history of more than six years, and those currently working either 12 hour shifts or rotational shifts were more likely to have metabolic syndrome.

Metabolic syndrome was present in eight per cent of those working shifts for less than six years, in 18 per cent in those working shifts for six to 15 years, and in 74 percent of those working shifts for more than 15 years. While the increase in prevalence of risk factors is also associated with age, the influence of the combination of older age and shift work on risk raises concern.

"Just how shift work contributes to the development of such risk factors isn't clear," says Dr. Tranmer. "It is possible that the disruption of biological rhythms, sleeping, eating, and exercise patterns may be factors." The research team is exploring these potential pathways in a current study.

A Statistics Canada survey on the work-life balance of shift workers found that long work hours were associated with role overload. Shift workers were more likely to cut back on sleep, to spend less time with their spouse, and to worry about not spending enough time with family, compared with regular day workers.

"All women should manage their weight and other risk factors, and this study shows women working shift work especially need to be aware," said Heart and Stroke Foundation spokesperson Dr. Beth Abramson. "We spend so many of our hours and days at work, it is important for employers and employees to create as healthy a work environment as possible - especially for shift workers."

She says that, given the prevalence of these cardiovascular risk factors, and in particular with abdominal obesity rates and the increasing age of the female hospital workforce, this study raises the need to examine workplace policy encouraging healthy behaviours for all employees.

She recommends that women find out how they can protect their heart health through the Foundation's The Heart Truth™ campaign (thehearttruth.ca), which educates women about identifying their risks and warning signs of heart disease and stroke, and shows them how to make lifestyle changes and take action to reduce their risk by as much as 80 per cent.

"These women work so hard caring for others, but they need to take the time to properly care of their own health," says Dr. Tranmer.

According to Statistics Canada, over 4 million workers aged 19 to 64 worked something other than a regular day shift in 2005. Of these shift workers, about 3.3 million worked full time (30 or more hours a week). Rotating shifts and irregular schedules were the most common types of shift work, accounting for 2.3 million full-time workers. Women made up 37 per cent of all full-time shift workers. The majority of women working shifts (69 per cent) worked part time.

When asked if similar conclusions could be drawn for male shift workers, Dr. Tranmer said that much of our understanding about the associations between shift work and health come from studies that have predominantly included men so she wanted to focus on the link in women.

Sunday, October 23, 2011

Cancer Drug May Also Treat Chronic Fatigue Syndrome

Cancer Drug May Also Treat Chronic Fatigue Syndrome

Rituximab Reduced Fatigue in 67% of Patients in Study

Researchers in Norway say they've been able to treat symptoms of chronic fatigue syndrome by giving patients a biologic drug that affects the immune system.
The drug, rituximab (Rituxan), works by depleting immune cells called B-cells. It is FDA approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and two kinds of vasculitis.
For the study, researchers recruited 30 people with chronic fatigue syndrome (CFS). Half got two infusions of rituximab given two weeks apart. The other half got infusions of saline solution as a placebo.

Ten patients in the rituximab group (67%) and two patients in the placebo group (13%) saw at least moderate reductions in fatigue.
In most of the patients, improvements were transient and faded within eight to 44 weeks.
But three patients, two in the rituximab group and one that got the placebo, continue to be symptom free 2 1/2 years after their treatments. Those three patients have all returned to full-time jobs, researchers say.

The study is published in the journal PLoS One.
"Our thought is that in fact CFS is an autoimmune disease in most patients," says study researcher Olav Mella, MD, PhD, an oncologist at Haukeland University Hospital in Bergen, Norway.

Mella and his colleague, Oystein Fluge, MD, PhD, say they accidentally discovered that rituximab might help chronic fatigue syndrome after they used it to treat three patients who suffered from both CFS and non-Hodgkin's lymphoma. All three patients reported significant improvements in fatigue after rituximab infusions. They eventually relapsed and were given more doses of rituximab. All three again had improvements in their CFS, though those eventually faded.
Their cases were reported in BioMedCentral Neurology in 2009.

Is Chronic Fatigue Syndrome an Autoimmune Disease?

Researchers say they aren't sure why the drug is working.
"We cannot know for sure, but what we see is that there's a delay from the rapid B-cell depletion after rituximab treatment to the clinical response. The delay can be from three to perhaps eight months before the response is thought to occur," says Fluge, who is an oncologist and medical physicist at Haukeland Hospital.
B-cells are part of the immune system. They roam the body in relatively small numbers searching for foreign invaders. When a B-cell finds one, it springs into action, becoming an infection-fighting chemical factory.
In some diseases, like leukemia, B-cells may go haywire and cause cancer. In rheumatoid arthritis, B-cells may attack the body's own tissues.
In CFS, however, it's unclear why killing off B-cells might help.
One theory, held by researchers who believe CFS may be caused by an infection, suggests that retroviruses may hide out in dormant B-cells, only becoming active when the cell is triggered and rapidly multiplies.
But Fluge thinks if that's the case, patients would see quicker improvements after taking the rituximab.

"We think what we see could be best explained with an autoimmune mechanism and gradual elimination of auto-antibodies," he says.
Other, more circumstantial evidence supports the idea that CFS may be an autoimmune disease.

Like other autoimmune conditions, it tends to be much more common in women than in men, for example. Many people report getting CFS after a bout with triggering illness. The risk of getting chronic fatigue appears be similar to the risk for getting other kinds of immune disorders.

More Research Needed

Despite the positive results of the study, researchers stressed that it was far too early for people with chronic fatigue to seek treatment with rituximab.
"For the time being, this is a clinical trial. It is not for routine use. We need at least one more large study, partly here and partly somewhere else, to confirm the results," Mella says.
Rituximab is expensive. A single course of treatment for cancer can cost more than $20,000. Rarely, fatal reactions have been reported after infusions of the drug, although no significant adverse events were reported in the current study.
"The most exciting news from the study is the possibility of disease-modifying treatment for at least some people with CFS," Kim McCleary, president and chief executive officer of the CFIDS Association of America, says in an email. "This study also provides support for other possible approaches to repair immune abnormalities that have been identified in CFS patients."
SOURCES: Fluge, O. PLoS One, October 2011.Olav Mella, MD, PhD, oncologist, Haukeland University Hospital, Bergen, Norway.Oystein Fluge, MD, PhD, oncologist and medical physicist, Haukeland University Hospital, Bergen, Norway.Kim McCleary, president and chief executive officer, CFIDS Association of America. ©2011

 
Design by Free WordPress Themes | Bloggerized by Lasantha -